MorphoSys AG Stock

Price

Target price

/ Tradegate WKN: 663200 / Name: MorphoSys / Stock / Biotechnology & Medical Research / Mid Cap /

Latest predictions

buy

Best running prediction

buy

Your prediction

MorphoSys AG Stock

The MorphoSys AG stock is trending slightly upwards today, with an increase of €0.35 (0.540%) compared to yesterday's price.

With 7 Buy predictions and not the single Sell prediction the community is currently very high on MorphoSys AG.

On the other hand, the target price of 65 € is below the current price of 65.35 € for MorphoSys AG, so the potential is actually -0.54%.

Our community identified positive and negative aspects for MorphoSys AG stock for the coming years. 6 users see the criterium "Worthwhile Investment for the next years" as a plus for the MorphoSys AG stock. On the other hand our users think that "General Risks" could be a problem in the future.

MorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.

Feedback

Pros and Cons of MorphoSys AG in the next few years

Pros

W********* I********* f** t** n*** y****

B****

S********** s********

Cons

G***** c******* t* c**********

M***** P*******

C******** o* t** e**********

Tell us your opinion to access the 'Wisdom of the Crowds'

Your Opinion

Legal notice

Performance of MorphoSys AG vs. its peers

Security	Change(%)	1w	1m	1y	YTD	3y	5y
MorphoSys AG
Evotec SE
Sage Therapeutics Inc.
Novocure Ltd

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.

Last updated at 2023-05-20

MorphoSys, a company in the Biotechnology & Medical Research industry, seems to have experienced a mixed financial performance in recent years. A quick glance at the financials indicates a trend of fluctuating figures across various metrics. The company's total assets, liabilities, and stockholder's equity have seen considerable shifts over time, ultimately leading to an overall mixed impression of the company's financial status.

*Pros: *

Growth in Total Assets: The company's total assets increased from €1,659,513,020 in 2020 to €2,556,254,216 in 2021, demonstrating a remarkable growth. Although the figures decreased slightly to €2,396,932,263 in 2022, the overall trend points towards a healthy financial condition.

Feedback